Anzeige
Mehr »
Freitag, 27.06.2025 - Börsentäglich über 12.000 News
Blockbuster-Bohrergebnisse: Gold-Antimon-Fund in Nevada trifft geopolitischen Nerv
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A4197V | ISIN: US55083R2031 | Ticker-Symbol:
NASDAQ
27.06.25 | 15:30
9,040 US-Dollar
-1,09 % -0,100
1-Jahres-Chart
LYELL IMMUNOPHARMA INC Chart 1 Jahr
5-Tage-Chart
LYELL IMMUNOPHARMA INC 5-Tage-Chart

Aktuelle News zur LYELL IMMUNOPHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
LYELL IMMUNOPHARMA Aktie jetzt für 0€ handeln
DoLyell Immunopharma, Inc. - 8-K, Current Report1
DiLyell Immunopharma price target raised to $10 from $1 at H.C. Wainwright1
MoLyell Immunopharma, Inc: Lyell Immunopharma to Participate in the H.C. Wainwright "HCW@Home" Series3
17.06.Lyell Immunopharma, Inc. - 8-K, Current Report1
17.06.Lyell Immunopharma, Inc: Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma64LYL314 demonstrated robust clinical responses, with an 88% overall response rate and a 72% complete response rate in patients treated in the third- or later-line setting (N = 25)71% of patients with...
► Artikel lesen
10.06.Lyell Immunopharma strengthens clinical and commercial capabilities with executive appointments4
09.06.Lyell Immunopharma, Inc. - 8-K, Current Report2
09.06.Lyell Immunopharma, Inc: Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments79Mark J. Bachleda, PharmD, MBA appointed as independent member of the Board of DirectorsDavid Shook, MD appointed as Chief Medical Officer, Mark Meltz, JD as General Counsel and Corporate Secretary...
► Artikel lesen
21.05.Lyell Immunopharma, Inc. - 8-K, Current Report1
14.05.Lyell Immunopharma reports Q1 results2
13.05.Lyell Immunopharma, Inc. - 10-Q, Quarterly Report1
13.05.Lyell Immunopharma, Inc. - 8-K, Current Report1
13.05.Lyell Immunopharma, Inc: Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025198Presenting new clinical data from Phase 1/2 multi-center clinical trial of LYL314, a next-generation dual-targeting CD19/CD20 CAR T-cell product candidate for the treatment of relapsed and/or refractory...
► Artikel lesen
15.04.Lyell Immunopharma gets FDA RMAT status for lymphoma treatment1
15.04.Lyell Immunopharma, Inc: Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma135RMAT designation was granted based on promising clinical data from the ongoing Phase 1/2 trial of LYL314 in patients with relapsed and/or refractory large B-cell lymphoma.RMAT designation recognizes...
► Artikel lesen
01.04.Lyell Immunopharma, Inc. - 8-K, Current Report5
11.03.Lyell Immunopharma reports Q4 results2
11.03.Lyell Immunopharma, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
11.03.Lyell Immunopharma, Inc. - 10-K, Annual Report2
11.03.Lyell Immunopharma, Inc: Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024153Acquired ImmPACT Bio and strengthened clinical pipeline with the addition of IMPT-314, a next-generation dual-targeting CD19/CD20 CAR T-cell product candidate for the treatment of aggressive large...
► Artikel lesen
Weiter >>
25 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1